2015
DOI: 10.1097/cji.0000000000000076
|View full text |Cite
|
Sign up to set email alerts
|

Delayed Dermatologic Hypersensitivity Reaction Secondary to Ipilimumab

Abstract: The treatment of melanoma has long favored the use of immunologic agents. Ipilimumab is a monoclonal antibody used to enhance the immune response. This therapy is associated with a variety of adverse reactions including skin reactions. Although dermatologic toxicities associated with the use of ipilimumab are common, delayed hypersensitivity reactions related to the drug have yet to be identified. This report is believed to be the first case of a delayed, severe dermatologic drug-related reaction secondary to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
17
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(17 citation statements)
references
References 2 publications
0
17
0
Order By: Relevance
“…The main toxicities during the use of ipilimumab are autoimmune skin events (rash and itching) [10], gastrointestinal events (diarrhea) [6,7], and long-term reactions, such as vitiligo, hypopituitarism and cholelithiasis [6]. Nevertheless, the patient in our study showed no adverse reactions during treatment and no signs of autoimmune reactions later.…”
Section: Scalp Melanoma Treated With Ipilimumab In Elderly Patientmentioning
confidence: 54%
“…The main toxicities during the use of ipilimumab are autoimmune skin events (rash and itching) [10], gastrointestinal events (diarrhea) [6,7], and long-term reactions, such as vitiligo, hypopituitarism and cholelithiasis [6]. Nevertheless, the patient in our study showed no adverse reactions during treatment and no signs of autoimmune reactions later.…”
Section: Scalp Melanoma Treated With Ipilimumab In Elderly Patientmentioning
confidence: 54%
“…Dermatological toxicity from immune checkpoint inhibitors (ICPI) is the most common irAE [5] and usually develops within the first 10 weeks of immunotherapy [10] in any tumour type [11,12] with a small percentage of patients developing delayed skin toxicity [13]. The incidence of any grade rash is of the order of 24.3% in patients treated with Ipilimumab of which 2.4% experienced grade 3 and 4 rash [12], 25.4 % in patients treated with anti-PD-1 therapy alone and 40.3% in the anti-CTLA-4 and antiPD-1 combination treatment [2].…”
Section: Dermatological Toxicitymentioning
confidence: 99%
“…In patients with grade 3 rash (>30% BSA), the treatment should be withheld until the rash resolves to grade 1 or lower, and the patient should be treated with intravenous corticosteroids (1-2 mg/kg/day of methylprednisolone or equivalent) which should be weaned off within four weeks [7,11,13]. In addition, dermatological advice should be sought for consideration of skin biopsy [7].…”
Section: Dermatological Toxicitymentioning
confidence: 99%
See 1 more Smart Citation
“…Dermatological toxicity is the most common and the earliest developed irAE, typically occurring within 3-4 weeks from treatment initiation (38). Delayed onset has been also reported (39). Clinical manifestations include maculopapular rash, pruritus and vitiligo.…”
Section: Dermatological Toxicitymentioning
confidence: 99%